By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our
Privacy Policy
for more information.
Accept
Deny
Preferences
Privacy
Privacy Preferences
Essential cookies
Required
Marketing cookies
Essential
Personalization cookies
Essential
Analytics cookies
Essential
Allow all cookies
Reject all cookies
Save preferences
Follow Us:
Subscribe
Thank you!
Oops!
Submit
About Proxima
Meet our Team
Why Proxima
Careers
We
Innovators
Our Expertise
Solutions
Regulatory
Clinical
Biotech
MedTech
Therapeutic Areas
Oncology
Pediatric
Cardiovascular
Orthopedics & Spine
Neuromodulation
General Surgery
In Vitro Diagnostics
Resources
Company updates
Newsletter
Company News
Blog
Events
Knowledge base
Industry Articles
FAQs
Glossary
Tools & Templates
Video Hub
Breakthrough Device Designation
Accelerator
Submit RFP
Submit RFP
FRequently Asked Questions
Are FDA inspections of clinical investigator sites announced or unannounced?
View All FAQs
About the Author
Alisa Survance
Director of Operations
Alisa’s overall goal through everything she has achieved at Proxima is to make it one of the most enjoyable places to work.
Read More >>
Both. They occur for any of the following reasons:
to verify data that has been submitted to the agency
if any complaints have been submitted in regard to that particular investigational site
if any sponsors have concerns
upon termination of the clinical site
to provide real-time assessment of the investigator’s conduct of the trial and protection of human subjects during an ongoing trial
at the request of an FDA review division
for trials that are being conducted on investigational products that have been identified as a product of special interest
More Questions? We're here to help!
SPEAK WITH A SPECIALIST